A Clinical Laboratory with Integrated Neuroscience (CLIN) for Early Evaluation of Medications for Substance Use Disorders
综合神经科学 (CLIN) 临床实验室,用于药物滥用障碍药物的早期评估
基本信息
- 批准号:10395761
- 负责人:
- 金额:$ 16.54万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-07-01 至 2024-01-31
- 项目状态:已结题
- 来源:
- 关键词:AdherenceAdjuvant AnalgesicAdministrative SupplementAgeAlcoholsAmbulatory CareAmericanAutomobile DrivingBaltimoreBehavioralBrainBrain imagingBuprenorphineCannabisCause of DeathClinicClinicalClinical TreatmentClinical TrialsCocaineCollaborationsCountryCuesData AnalysesDevelopmentDiseaseDopamineDoseDrug ScreeningDrug usageEnrollmentEthanolEvaluationFentanylGoalsGrantHeterogeneityHumanImageIndividualLaboratoriesLifeLiteratureMeasuresMedicalMethadoneMood DisordersNaltrexoneNational Institute of Drug AbuseNeurocognitionNeurosciencesNicotineObservational StudyOpioidOpioid agonistOutcomeOutpatientsParentsParticipantPatientsPennsylvaniaPharmaceutical PreparationsPhasePhenotypePhiladelphiaPittsburgh Sleep Quality IndexPlacebosPopulationRandomizedRelapseResearchResearch PersonnelResourcesRewardsRoleSavingsSiteSleepSpecific qualifier valueSpeedSubgroupSuboxoneSubstance Use DisorderSymptomsTestingTherapeuticUniversitiesUrineWithdrawal SymptomWorkaddictionclinical efficacycocaine usecravingdata miningdiariesexperienceillicit drug useillicit opioidimaging probeimprovedimprovement on sleepindexingmedication compliancemedication-assisted treatmentmortalityneuroimagingnon-opioid analgesicolanzapineopioid epidemicopioid mortalityopioid overdoseopioid useopioid use disorderoverdose deathphase 2 studypreventrecruitresponsescreeningsevere mental illnesssynthetic opioidtreatment adherencetreatment siteweek trial
项目摘要
The nation's grim opioid crisis surges on, with the fentanyls (high potency synthetic opioids) driving
unprecedented mortality rates. Drug overdose deaths are now the leading cause of death in those
under age 50, with more than 47,000 Americans dying of opioid overdose in 2017. As of December
2018, Philadelphia had the third highest rate of opioid overdose deaths in the country (out-ranked only
by Pittsburgh and Baltimore). Fentanyl is present in 84% of the fatal opioid overdoses in Philadelphia.
Medication-assisted treatment (MAT) for opioid use disorders – whether full opioid agonist
(methadone), partial opioid agonist (buprenorphine), or a full antagonist (naltrexone) – is critical for
reducing opioid use, and for preventing overdose deaths. Unfortunately, compliance with these life-
saving medications is often poor, with ancillary use of non-opioid drugs (especially cocaine) as a
common culprit. Cocaine is found in almost half of the opioid overdose deaths in Philadelphia.
Identifying promising adjunctive medications that reduce cocaine and other illicit drug use
during MAT could improve adherence and save thousands of lives each year. Further, measuring
how these medications “engage” the intended brain targets will speed rational medication
development. Toward both these goals, we have established a Clinical Laboratory with Integrated
Neuroscience (CLIN) for Evaluation of Medications for Substance Use Disorders at the University of
Pennsylvania Center for Studies of Addiction.
In the initial demonstration project for the UG1, we will test the promise of a dopamine D3-
preferring agent, cariprazine (Vraylar, 1.5 mg daily), vs. placebo both for (Aim 1) preliminary
clinical efficacy (reduced illicit drug use, and improved adherence to life-saving buprenorphine),
and (Aim 2) for target engagement (e.g., limbic activation by opioid and cocaine cues), in patients
with both opioid use disorder (OUD) and cocaine use disorder (CocUD), in an 8 week outpatient trial.
Recently, the UG1 Laboratory grants at UPenn and VCU have, in collaboration with NIDA,
proposed to screen a medication identified by data-mining, olanzapine, for clinical efficacy
(Primary Aim: reduction in illicit opioid use) in a two-site (n=24 per site), 8-week observational trial
for buprenorphine-stabilized OUD patients with symptoms of Serious Mental Illness (SMI).
Secondary Aims feature reduction in other illicit drug use and improvement in sleep; Exploratory
Aims include improvements in MAT adherence, in study retention, and in thought and mood
disorder symptoms. Both the initial demonstration project (cariprazine) and the olanzapine
participants will also receive a battery of phenotypic probes (e.g., for reward/inhibition;
neurocognition) to capture relapse vulnerability, and likely heterogeneity in medication response.
随着芬太尼(高效合成阿片类药物)的泛滥,美国严峻的阿片类药物危机仍在继续
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Anna Rose Childress其他文献
Can we use cue-related brain responses to predict which cocaine patients will take more risks?
- DOI:
10.1016/j.drugalcdep.2014.09.489 - 发表时间:
2015-01-01 - 期刊:
- 影响因子:
- 作者:
Zachary A. Monge;K. Jagannathan;Jesse Suh;Ronald Ehrman;Kimberly A. Young;Teresa Franklin;Daniel Langleben;Charles P. O’Brien;Anna Rose Childress - 通讯作者:
Anna Rose Childress
Frontal vs. limbic predictors of inhibitory success in addiction
- DOI:
10.1016/j.drugalcdep.2014.02.112 - 发表时间:
2014-07-01 - 期刊:
- 影响因子:
- 作者:
Anna Rose Childress;Y. Li;M. Goldman;J.J. Suh;R. Ehrman;S. Lam;Z. Singer;Teresa R. Franklin;D. Langleben;K. Young;Reagan R. Wetherill;Michael J. Gawrysiak;C.P. O’Brien - 通讯作者:
C.P. O’Brien
Baclofen, a GABA B Agonist, reduces risk-taking and reveals the relationship between brain responses to drug cues and risk-taking in cocaine-addicted patients
- DOI:
10.1016/j.drugalcdep.2014.02.684 - 发表时间:
2014-07-01 - 期刊:
- 影响因子:
- 作者:
Kimberly A. Young;Y. Li;D.C.S. Roberts;C. Lejuez;Teresa R. Franklin;Jesse Suh;M. Goldman;Kyle M. Kampman;Reagan R. Wetherill;C.P. O’Brien;Anna Rose Childress - 通讯作者:
Anna Rose Childress
Differential brain response to successful and failed response inhibition: Cocaine-dependent vs. healthy subjects
- DOI:
10.1016/j.drugalcdep.2015.07.582 - 发表时间:
2015-11-01 - 期刊:
- 影响因子:
- 作者:
Jesse Suh;K. Jagannathan;Ronald Ehrman;Marina Goldman;Zachary A. Monge;Elliott Berkowitz-Sturgis;Teresa Franklin;Kathleen Marquez;Regina Szucs-Reed;Charles P. O’Brien;Anna Rose Childress - 通讯作者:
Anna Rose Childress
Lower oxidative stress in umbilical blood cord of newborns exposed to crack during pregnancy
- DOI:
10.1016/j.drugalcdep.2014.09.676 - 发表时间:
2015-01-01 - 期刊:
- 影响因子:
- 作者:
Claudia M. Szobot;Maria Zavaschi;V. Mardini;F. Kapczinski;Márcia Kauer-Sant’anna;Gabriela Colpo;Bianca Aguiar;Gabrielle Cunha;L. Manna;Anna Rose Childress;Daniel Langleben;K.M. Cereser;L.A. Rohde - 通讯作者:
L.A. Rohde
Anna Rose Childress的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Anna Rose Childress', 18)}}的其他基金
A Clinical Laboratory with Integrated Neuroscience (CLIN) for Early Evaluation of Medications for Substance Use Disorders
综合神经科学 (CLIN) 临床实验室,用于药物滥用障碍药物的早期评估
- 批准号:
10348202 - 财政年份:2020
- 资助金额:
$ 16.54万 - 项目类别:
A Clinical Laboratory with Integrated Neuroscience (CLIN) for Early Evaluation of Medications for Substance Use Disorders
综合神经科学 (CLIN) 临床实验室,用于药物滥用障碍药物的早期评估
- 批准号:
10576815 - 财政年份:2020
- 资助金额:
$ 16.54万 - 项目类别:
A Clinical Laboratory with Integrated Neuroscience (CLIN) for Early Evaluation of Medications for Substance Use Disorders
综合神经科学 (CLIN) 临床实验室,用于药物滥用障碍药物的早期评估
- 批准号:
9895139 - 财政年份:2020
- 资助金额:
$ 16.54万 - 项目类别:
Targeting dopamine D3 receptors in cocaine addiction
靶向可卡因成瘾中的多巴胺 D3 受体
- 批准号:
9249538 - 财政年份:2016
- 资助金额:
$ 16.54万 - 项目类别:
Targeting dopamine D3 receptors in cocaine addiction
靶向可卡因成瘾中的多巴胺 D3 受体
- 批准号:
9926357 - 财政年份:2016
- 资助金额:
$ 16.54万 - 项目类别:
T32 Translational Addiction Research Fellowship Program
T32 转化成瘾研究奖学金计划
- 批准号:
9393067 - 财政年份:2016
- 资助金额:
$ 16.54万 - 项目类别:
Weight History, Brain Activation to Food Cues and Eating Disorder Psychopathology
体重史、食物线索的大脑激活和饮食失调精神病理学
- 批准号:
8678241 - 财政年份:2014
- 资助金额:
$ 16.54万 - 项目类别:
Weight History, Brain Activation to Food Cues and Eating Disorder Psychopathology
体重史、食物线索的大脑激活和饮食失调精神病理学
- 批准号:
9076365 - 财政年份:2014
- 资助金额:
$ 16.54万 - 项目类别:
Do brain differences influence HIV risk behavior? A study of young urban women
大脑差异会影响艾滋病毒危险行为吗?
- 批准号:
8513416 - 财政年份:2012
- 资助金额:
$ 16.54万 - 项目类别:
Do brain differences influence HIV risk behavior? A study of young urban women
大脑差异会影响艾滋病毒危险行为吗?
- 批准号:
8330061 - 财政年份:2012
- 资助金额:
$ 16.54万 - 项目类别: